CN Patent

CN102274517B — 治疗帕金森病的方法

Assigned to Newron Pharmaceuticals SpA · Expires 2018-08-31 · 8y expired

What this patent protects

本发明描述了safinamide、safinamide衍生物和MAO‑B抑制剂在新类型帕金森病治疗中的新用途。更具体的说，本发明涉及通过施用safinamide、safinamide衍生物或MAO‑B抑制剂与其它帕金森病活性剂或疗法如左旋多巴/PDI或多巴胺激动剂的组合来治疗帕金森病的方法。

USPTO Abstract

本发明描述了safinamide、safinamide衍生物和MAO‑B抑制剂在新类型帕金森病治疗中的新用途。更具体的说，本发明涉及通过施用safinamide、safinamide衍生物或MAO‑B抑制剂与其它帕金森病活性剂或疗法如左旋多巴/PDI或多巴胺激动剂的组合来治疗帕金森病的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN102274517B
Jurisdiction
CN
Classification
—
Expires
2018-08-31
Drug substance claim
No
Drug product claim
No
Assignee
Newron Pharmaceuticals SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.